Summer Sale
50% off Premium Yearly
00days
00hrs
00mins
00secs
Opinions Jim Cramer - Mad Money
BillionToOneBLLNPARTIAL BUYNov 14, 2025
N/A
Stock price when the opinion was issued
Healthcare
It's the ideal tool to help you make quicker, more informed decisions for managing and tracking your investments.
They had an impressive IPO recently. They make genetic tests to detect diseases early. Their technology is superb and is ahead of their competition. Since 2021, sales have been rising at 167% compounded annually. Last year saw 113% revenue growth. Q3 guidance declared revenue growth at 112-120%. EBITDA turned positive earlier this year. Excellent growth and profitable. Also, they have a clean balance sheet. However, the stock has already seen a pullback, so there's volatility. Wants to see shares fall further to make it more attractive.